CorMedix Inc (NASDAQ:CRMD – Get Free Report) Director Myron Kaplan bought 25,000 shares of the company’s stock in a transaction on Monday, November 16th. The stock was purchased at an average cost of $4.88 per share, for a total transaction of $122,000.00. Following the completion of the transaction, the director directly owned 256,487 shares of the company’s stock, valued at approximately $1,251,656.56. The trade was a 10.80% increase in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
CorMedix Trading Up 3.7%
CorMedix stock opened at $5.27 on Friday. The business has a 50-day simple moving average of $6.86 and a two-hundred day simple moving average of $7.49. The company has a market cap of $419.18 million, a P/E ratio of 3.74, a P/E/G ratio of 1.11 and a beta of 1.48. CorMedix Inc has a 52-week low of $4.47 and a 52-week high of $13.02. The company has a quick ratio of 2.36, a current ratio of 2.43 and a debt-to-equity ratio of 0.31.
CorMedix (NASDAQ:CRMD – Get Free Report) last issued its quarterly earnings data on Thursday, November 12th. The company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.07). The business had revenue of $54.52 million during the quarter, compared to the consensus estimate of $51.76 million. CorMedix had a return on equity of 26.70% and a net margin of 15.49%. Analysts predict that CorMedix Inc will post 0.44 EPS for the current year.
Analysts Set New Price Targets
Several research analysts have weighed in on the stock. Oppenheimer reiterated an “outperform” rating and issued a $13.00 price target (down from $15.00) on shares of CorMedix in a research report on Friday, November 13th. Wall Street Zen downgraded shares of CorMedix from a “hold” rating to a “sell” rating in a research report on Saturday, November 14th. Weiss Ratings downgraded shares of CorMedix from a “hold (c+)” rating to a “hold (c)” rating in a research report on Tuesday, November 10th. Needham & Company LLC upped their price objective on CorMedix from $12.00 to $14.00 and gave the stock a “buy” rating in a research note on Tuesday, November 10th. Finally, Royal Bank Of Canada upped their price objective on CorMedix from $14.00 to $15.00 and gave the stock an “outperform” rating in a research note on Tuesday, November 10th. Eight investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $15.22.
Get Our Latest Analysis on CRMD
Institutional Inflows and Outflows
Large investors have recently made changes to their positions in the stock. China Universal Asset Management Co. Ltd. increased its holdings in CorMedix by 13.9% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 14,222 shares of the company’s stock worth $113,000 after acquiring an additional 1,736 shares in the last quarter. HighTower Advisors LLC lifted its holdings in CorMedix by 8.2% during the second quarter. HighTower Advisors LLC now owns 32,655 shares of the company’s stock valued at $256,000 after purchasing an additional 2,476 shares in the last quarter. Sigma Planning Corp lifted its holdings in CorMedix by 8.5% during the third quarter. Sigma Planning Corp now owns 32,142 shares of the company’s stock valued at $247,000 after purchasing an additional 2,531 shares in the last quarter. Advisors Asset Management Inc. bought a new position in shares of CorMedix in the third quarter worth approximately $26,000. Finally, Mirae Asset Global Investments Co. Ltd. bought a new position in shares of CorMedix in the third quarter worth approximately $31,000. 34.18% of the stock is owned by hedge funds and other institutional investors.
CorMedix Company Profile
CorMedix Inc. is a biopharmaceutical company focused on products for infectious and inflammatory diseases. Its lead product, DefenCath, is an antimicrobial catheter-lock solution containing taurolidine and heparin. The U.S. Food and Drug Administration approved it to reduce catheter-related bloodstream infections in adults with kidney failure who receive chronic hemodialysis through a central venous catheter. CorMedix expanded its business in 2024 by acquiring Melinta Therapeutics, adding marketed antibiotics to its portfolio.
Read More
- Five stocks we like better than CorMedix
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Receive News & Ratings for CorMedix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CorMedix and related companies with MarketBeat.com's FREE daily email newsletter.
